Kiniksa Projects $980M-$995M in Revenue for 2026 as KPL-387 Advances to Phase III
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has projected revenue of between $980 million and $995 million for the year 2026. The company is advancing its drug candidate, KPL-387, into Phase III clinical trials under the PASTORALE study. CEO Sanj Patel stated that Kiniksa remains in a strong position as it continues to execute across its portfolio. The update comes amid ongoing development efforts and reflects confidence in the company's pipeline progress. The projected revenue range indicates continued growth expectations for 2026, supported by clinical advancements.
Tickers: $KNSA